Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Human Visceral Adipose Tissue Macrophages Are Not Adequately Defined by Standard Methods of Characterization.

Blaszczak AM., Jalilvand A., Liu J., Wright VP., Suzo A., Needleman B.

Prospective Study with a reported sample of 50 on Type 2 Diabetes, published in J Diabetes Res (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Diabetes Res (2019)
Country
United States
Reported sample size
50
Source database
PubMed
PMID
30719456
PMCID
PMC6335856
DOI
10.1155/2019/8124563
Citations
15

Abstract (original English)

Obesity is associated with a state of chronic low-grade inflammation both systemically and within specific tissues, including adipose tissue (AT). In murine models of obesity, there is a shift in the inflammatory profile of the AT immune cells, with an accumulation of proinflammatory M1 macrophages that surround the expanding adipocyte. However, much less is known about the immune cell composition and how to best define AT macrophages in humans. Objective . The goals of the current study were to determine the contribution of macrophages to the stromal vascular fraction (SVF) in lean versus obese human visceral AT (VAT); examine the expression of common M1, M2, and pan macrophage markers; and determine the association of specific macrophage types with known biomarkers of obesity-related cardiometabolic disease. Research Design and Methods . VAT biopsies were obtained from obese ( n = 50) and lean ( n = 8) patients during elective surgery. Adipocytes and SVF were isolated, and the SVF was subjected to flow cytometry analyses. Results . Our results indicate that VAT macrophages are increased in obesity and associate with biomarkers of CVD but that many macrophages do not fall into currently defined M1/M2 classification system based on CD206 receptor expression levels. Conclusions . VAT macrophages are increased in obese subjects, but the current markers used to define macrophage p

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdiponectinAdultFemaleHumansInflammationInsulin ResistanceIntra-Abdominal FatLeptinMacrophagesMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research